BACKGROUND & AIMS: Fibrosis progression might be accelerated in patients who are coinfected with human immunodeficiency virus (HIV) and HCV (HIV/HCV). However, no studies have directly compared fibrosis progression by paired liver biopsy between patients infected with HIV and HCV versus those infected with only HCV. METHODS: Liver biopsy samples were collected from patients with HIV/HCV (n = 306) and those with HCV; biopsies from 59 without a sustained virologic response (SVR) or cirrhosis were matched with those from patients with only HCV (controls) for initial fibrosis stage, demographics, and HCV treatment. For HIV/HCV patients, categorical variables at baseline and the area under the curve of continuous variables per unit time were analyzed for associations with fibrosis progression. RESULTS: Liver biopsies from HIV/HCV patients had more piecemeal necrosis than controls (P = .001) and increased lobular inflammation (P = .002); HIV/HCV patients also had shorter intervals between liver biopsies (4.7 vs 5.9 years, P < .0001). Between the first and second biopsies, fibrosis remained unchanged or progressed 1 or 2 units in 55%, 18%, and 18% of HIV/HCV patients, respectively, compared with 45%, 30%, and 9% of controls. The fibrosis progression rate was similar between HIV/HCV and control patients (0.12 ± 0.40 vs 0.091 ± 0.29 units/y; P = .72). In paired biopsies from 66 patients, including those with SVR, there were no associations between fibrosis progression and demographics; numbers of CD4+ T cells; levels of aspartate aminotransferase or alanine aminotransferase; use of highly active antiretroviral therapy; response to HCV therapy (no treatment, SVR, or non-response); baseline levels of FIB-4; or histologic features including inflammation, fibrosis, or steatosis. CONCLUSIONS: On the basis of analysis of liver biopsy samples, fibrosis progression was similar between HIV/HCV-infected and HCV-infected patients; no clinical or laboratory parameters predicted disease progression.
BACKGROUND & AIMS:Fibrosis progression might be accelerated in patients who are coinfected with human immunodeficiency virus (HIV) and HCV (HIV/HCV). However, no studies have directly compared fibrosis progression by paired liver biopsy between patients infected with HIV and HCV versus those infected with only HCV. METHODS: Liver biopsy samples were collected from patients with HIV/HCV (n = 306) and those with HCV; biopsies from 59 without a sustained virologic response (SVR) or cirrhosis were matched with those from patients with only HCV (controls) for initial fibrosis stage, demographics, and HCV treatment. For HIV/HCVpatients, categorical variables at baseline and the area under the curve of continuous variables per unit time were analyzed for associations with fibrosis progression. RESULTS: Liver biopsies from HIV/HCVpatients had more piecemeal necrosis than controls (P = .001) and increased lobular inflammation (P = .002); HIV/HCVpatients also had shorter intervals between liver biopsies (4.7 vs 5.9 years, P < .0001). Between the first and second biopsies, fibrosis remained unchanged or progressed 1 or 2 units in 55%, 18%, and 18% of HIV/HCVpatients, respectively, compared with 45%, 30%, and 9% of controls. The fibrosis progression rate was similar between HIV/HCV and control patients (0.12 ± 0.40 vs 0.091 ± 0.29 units/y; P = .72). In paired biopsies from 66 patients, including those with SVR, there were no associations between fibrosis progression and demographics; numbers of CD4+ T cells; levels of aspartate aminotransferase or alanine aminotransferase; use of highly active antiretroviral therapy; response to HCV therapy (no treatment, SVR, or non-response); baseline levels of FIB-4; or histologic features including inflammation, fibrosis, or steatosis. CONCLUSIONS: On the basis of analysis of liver biopsy samples, fibrosis progression was similar between HIV/HCV-infected and HCV-infectedpatients; no clinical or laboratory parameters predicted disease progression.
Authors: Y Benhamou; V Di Martino; M Bochet; G Colombet; V Thibault; A Liou; C Katlama; T Poynard Journal: Hepatology Date: 2001-08 Impact factor: 17.425
Authors: Richard K Sterling; Mary S Wilson; Arun J Sanyal; Velimir A Luketic; R Todd Stravitz; Melissa J Contos; A Scott Mills; Mitchell L Shiffman Journal: Clin Gastroenterol Hepatol Date: 2004-05 Impact factor: 11.382
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Marc G Ghany; David E Kleiner; Harvey Alter; Edward Doo; Farooq Khokar; Kittichai Promrat; David Herion; Yoon Park; T Jake Liang; Jay H Hoofnagle Journal: Gastroenterology Date: 2003-01 Impact factor: 22.682
Authors: Richard K Sterling; Melissa J Contos; Arun J Sanyal; Velimir A Luketic; R Todd Stravitz; Mary S Wilson; A Scott Mills; Mitchell L Shiffman Journal: J Acquir Immune Defic Syndr Date: 2003-01-01 Impact factor: 3.731
Authors: A H Mohsen; P J Easterbrook; C Taylor; B Portmann; R Kulasegaram; S Murad; M Wiselka; S Norris Journal: Gut Date: 2003-07 Impact factor: 23.059
Authors: C Sagnelli; C Uberti-Foppa; G Pasquale; S De Pascalis; N Coppola; L Albarello; C Doglioni; A Lazzarin; E Sagnelli Journal: Infection Date: 2013-07-10 Impact factor: 3.553
Authors: D Silver; G Karnik; A Osinusi; R Silk; L Stabinski; L Doonquah; S Henn; G Teferi; H Masur; S Kottilil; D Fishbein Journal: Clin Infect Dis Date: 2013-02-01 Impact factor: 9.079
Authors: Jennifer C Price; Eric C Seaberg; John P Phair; Mallory D Witt; Susan L Koletar; Chloe L Thio Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Richard K Sterling; Wendy C King; Mandana Khalili; Raymond T Chung; Mark Sulkowski; Mamta K Jain; Mauricio Lisker-Melman; Marc G Ghany; David K Wong; Amanda S Hinerman; Atul K Bhan; Abdus S Wahed; David E Kleiner Journal: Hepatology Date: 2021-08-25 Impact factor: 17.298